Labcorp Perspectives: Oncology

In this episode of Labcorp Perspectives Oncology, Dr. Rebecca Previs sits down with Dr. Shakti Ramkissoon, Senior Vice President of Enterprise Oncology and Diagnostic Medical Affairs, to unpack key insights from Labcorp’s latest report, "The Pulse of the Pathologist."

Discover how rising cancer volumes, smaller biopsies, and workforce pressures are transforming the pathologist’s role—from the lab bench to digital workflows and AI-powered diagnostics. The conversation dives into hot topics including how digital pathology and remote reading provide flexibility, efficiency, and democratize expertise, as well as how AI is emerging as a performance enhancer—taking on repetitive tasks, helping with turnaround times, and ensuring the pathologist stays at the center of decision-making. 

Hear how pathologists are meeting complexity head-on to deliver faster, clearer answers for patients and oncologists, and what the future holds as technology and medicine evolve together. Tune in now.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this inspiring episode of Labcorp Perspectives Oncology, Dr. Rebecca Previs sits down with 16-year-old Hodgkin’s lymphoma survivor Mira Hallman Poran. Hear Mira’s honest account of discovering something was wrong, facing misdiagnoses, managing fears like losing her hair, and maintaining her passions—music, lifeguarding, and friendships—through cancer treatment.

Mira shares what it’s really like to be a teenager with cancer: navigating school, friendships, and normal life while fighting for her health. From the power of community to finding self-appreciation and hope, this conversation is a must-listen for families, young cancer patients, and their support networks.

Discover how connection, persistence, and a strong care team helped Mira thrive on her toughest days, and what advice she has for others facing their own battles.

Tune in for real talk on resilience, support, and finding the joy in everyday victories.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Andrew Satterlee, Dr. Breanna Mann, and Dr. Shawn Hingtgen to break down a groundbreaking shift in how doctors choose cancer treatments for patients.

Their solution, SLICE (Screening Live Cancer Explants), is changing the speed and accuracy with which clinicians can predict which therapies will work—especially for tough-to-treat tumors like glioblastoma. Discover why traditional genomic testing doesn’t always provide the answers patients need, and how SLICE delivers drug response results using live patient tumor tissue within just four days. The team explains the science, shares real-world findings, and discusses how functional assays like SLICE aim to improve outcomes, cut down the trial-and-error, and could soon guide clinical practice and CAR T cell therapy decisions.

Catch this episode now to see what’s next for making cancer care faster, smarter, and more patient-focused.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does nuclear grading really reveal in the modern molecular era of endometrial cancer care?

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs, Senior Director of Medical Affairs, sits down with gynecologic pathologist Dr. Tricia Numan and anatomic and molecular pathologist Dr. Kyle Strickland to unpack the surprising findings from their USCAP-presented study.

Step into the pathologist’s perspective as the team breaks down how tumor grading is performed, why nuclear atypia matters, and the sometimes-conflicting role of molecular testing like MSI and TP53. Discover why grading variability among experts can shift treatment plans—and how more standardized criteria and emerging AI tools could transform future diagnostics.

Whether you’re a practicing pathologist, oncologist, or keen to understand the future of cancer diagnostics, this episode delivers insights on integrating traditional morphology with next-generation molecular profiling. Find out what’s next for endometrial cancer grading and how these innovations might impact clinical decisions worldwide.

Tune in now to hear what’s on the horizon for cancer grading and patient care.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this compelling episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by innovators Dr. Angeles Alvarez Secord and Dr. Aine Clements to discuss high-impact data on endometrial cancer, focusing on the landmark GOG258 trial through the lens of modern molecular classification.

The trio explores how integrating single-gene testing for markers such as POL-E, mismatch repair, and p53 mutations is redefining “high risk,” shifting treatment strategies, and offering new hope for patients with advanced endometrial cancer. Hear first-hand about the years-long research journey, the challenges of trial design, and what practice-changing insights these findings bring to clinicians and patients, particularly regarding treatment de-escalation, prognosis, and precision oncology.

Tune in now to learn how GOG258’s molecular analysis is shaping the future of personalized medicine in uterine cancer care.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes Dr. Brian Caveney, Labcorp’s Chief Medical and Scientific Officer, to unpack findings from the Pulse of the Oncologist report—a nationwide survey capturing the real-world perspectives of 152 oncologists across practice settings.

Together, Dr. Rebecca Previs and Brian Caveney dive into the pressing issues that shape oncology care today: the rising complexity of cancer treatment, the critical importance of diagnostic turnaround time, and how digital innovation can ease clinical workflows and reduce friction. They discuss why interpretive clarity in lab reports matters more than ever and spotlight the game-changing role of molecular residual disease (MRD) testing in monitoring and guiding patient care.

The conversation highlights practical solutions for improving access to advanced diagnostics, the emotional and financial burdens patients and providers face, and how health systems, labs, and payers must partner to drive equity and innovation.

Ready to hear what oncologists really want and what’s next for cancer care? Tune in now for essential insights that will reshape your view of the future of oncology.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics.

You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why integrating it with targeted therapies is essential for matching the right patient to the right treatment. Dawn McHugh guides us through real-world examples—from HER2 and EGFR to the latest in liquid biopsy—explaining how these diagnostics are expanding access, shaping new therapies, and accelerating the pace of cancer innovation. The conversation explores development timelines, regulatory hurdles, the value of early collaboration, and emerging technologies like AI and decentralized NGS.

Whether you’re an oncologist, researcher, or pharma partner, this episode delivers actionable insights on the present and future impact of CDXs in oncology care.

Tune in for a dynamic, forward-looking discussion and gain a new perspective on the science fueling tomorrow’s breakthroughs.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Kyle Strickland, Director of Medical Affairs and pathologist at Labcorp, and Dr. Erin Newburn, field application scientist and genomicist, for a deep dive into tissue stewardship and the pivotal role of FFPE specimens in precision oncology.

Together, the team demystifies how formalin-fixed paraffin-embedded (FFPE) samples have become the gold standard in both clinical and research settings for biomarker testing. They discuss the science behind tissue preservation, compare FFPE to fresh and frozen samples, and reveal the unique challenges these specimens present for next-generation sequencing. Explore the crucial pre-analytical factors influencing sample quality and how emerging innovations are pushing the boundaries of what’s possible in cancer diagnostics, clinical trials, and translational research.

Whether you’re a clinician seeking to optimize patient care, a researcher navigating limited samples, or simply curious about the future of precision medicine, this conversation provides practical insights and actionable tips directly from the experts transforming the field.

Tune in now to discover how the workhorse of pathology is powering a new era in oncology.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this insightful episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer.

Hear firsthand how the introduction of immune checkpoint blockade and an ultrasensitive tumor-informed ctDNA platform offers new hope for tracking and treating patients when imaging falls short. Dr. Sausen shares the technological breakthroughs behind molecular residual disease detection, the impact of ctDNA on progression-free survival, and practical challenges in implementing these assays across multicenter studies.

Whether you’re a clinician, researcher, or patient advocate, discover how molecular monitoring is changing the game for mesothelioma and rare cancers alike.

Tune in now to reimagine the future of oncology care.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs connects with Suzanne Garner, Senior Director of Strategic Partnerships at Outcomes4Me, to spotlight her remarkable journey as a breast cancer patient, advocate, and now leader in digital health. Suzanne shares her personal story, from an unexpected diagnosis and navigating overwhelming choices, to the pivotal discovery that empowered her to actively participate in her treatment decisions.

Together, they discuss the critical role of biomarker and genetic testing in shaping individualized treatment plans and the impact of patient-friendly technology, like the Outcomes4Me app, in driving health equity and expanding access to clinical trials. Learn how education, self-advocacy, and digital tools are changing the cancer care landscape, and why the partnership between patient and oncologist matters more than ever.

Tune in for hope, practical insights, and real-world tools for patients, providers, and caregivers alike.

Follow Us

• LinkedIn @labcorp
• X @labcorp
• Facebook @labcorp
• Instagram @labcorp
• YouTube @LabcorpVideo

Presented by Labcorp Oncology
 https://www.labcorp.com/oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.